Combo Products Demand Unique Cardiac Safety Assessment – FDA Think Tank
This article was originally published in The Gray Sheet
Executive Summary
The approval process for combination products should not be tied to the independent expectations for either drugs or devices, panelists stressed at the FDA/Duke Cardiovascular Research Institute "Cardiac Safety and the Critical Path Initiative Think Tank" Oct. 11 in Bethesda, Md